Incyte Corp (INCY) - Financial and Strategic SWOT Analysis Review

  • ID: 4302705
  • SWOT Analysis
  • 62 pages
  • GlobalData
  • Incyte Corporation
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Biogen Inc
  • CTI BioPharma Corp
  • GTx Inc
  • Senomyx Inc
  • MORE
Incyte Corp (INCY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Incyte Corp (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. JAKAFI is distributed principally through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd. (Norvatis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company’s pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, multiple tumor types, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

Incyte Corp Key Recent Developments

May 04,2017: Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs
Mar 02,2017: Incyte’s Targeted Therapy and Immuno-oncology Portfolio to be Featured in 20 Abstracts at the AACR Annual Meeting 2017
Feb 14,2017: Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs
Nov 03,2016: More Than 20 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 58th Annual ASH Meeting
Nov 01,2016: Incyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Biogen Inc
  • CTI BioPharma Corp
  • GTx Inc
  • Senomyx Inc
  • MORE
Section 1 - About the Company
Incyte Corp - Key Facts
Incyte Corp - Key Employees
Incyte Corp - Key Employee Biographies
Incyte Corp - Major Products and Services
Incyte Corp - Pharmaceutical Pipeline Products Data
Incyte Corp, Pipeline Products by Therapy Area
Incyte Corp, Pipeline Products by Development Phase
Incyte Corp - History
Incyte Corp - Company Statement
Incyte Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 - Company Analysis
Incyte Corp - Business Description
Incyte Corp - Corporate Strategy
Incyte Corp - SWOT Analysis
SWOT Analysis - Overview
Incyte Corp - Strengths
Incyte Corp - Weaknesses
Incyte Corp - Opportunities
Incyte Corp - Threats
Incyte Corp - Key Competitors

Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Incyte Corp, Recent Deals Summary

Section 5 - Company’s Recent Developments
May 04, 2017: Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs
Mar 02, 2017: Incyte’s Targeted Therapy and Immuno-oncology Portfolio to be Featured in 20 Abstracts at the AACR Annual Meeting 2017
Feb 14, 2017: Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs
Nov 03, 2016: More Than 20 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 58th Annual ASH Meeting
Nov 01, 2016: Incyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs
Aug 09, 2016: Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs
May 09, 2016: Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Apr 15, 2016: Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio
Feb 29, 2016: Incyte Joins Patient Organizations Worldwide in Recognition of Rare Disease Day 2016 to Make Patient Voices Heard
Feb 11, 2016: Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

Section 6 - Appendix
Methodology
Ratio Definitions

List of Tables
Incyte Corp, Key Facts
Incyte Corp, Key Employees
Incyte Corp, Key Employee Biographies
Incyte Corp, Major Products and Services
Incyte Corp, Number of Pipeline Products by Therapy Area
Incyte Corp, Number of Pipeline Products by Development Stage
Incyte Corp, History
Incyte Corp, Subsidiaries
Incyte Corp, Key Competitors
Incyte Corp, Ratios based on current share price
Incyte Corp, Annual Ratios
Incyte Corp, Annual Ratios (Cont...1)
Incyte Corp, Annual Ratios (Cont...2)
Incyte Corp, Interim Ratios
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Incyte Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Incyte Corp, Pipeline Products by Therapy Area
Incyte Corp, Pipeline Products by Development Phase
Incyte Corp, Performance Chart (2012 - 2016)
Incyte Corp, Ratio Charts
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Senomyx Inc
  • Regeneron Pharmaceuticals Inc
  • Lexicon Pharmaceuticals Inc
  • GTx Inc
  • CTI BioPharma Corp
  • Biogen Inc
  • Amgen Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll